Individualized Diagnostic and Treatment of Prostate Cancer
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Methodology, Drug and Device Discovery".
Deadline for manuscript submissions: closed (31 July 2020) | Viewed by 3367
Special Issue Editor
Special Issue Information
Dear Colleagues,
Prostate cancer (PCa) is characterized by extensive clinical and histomorphological heterogeneity and tumor multifocality. In recent years, considerable improvements have been made in the radiological (magnetic resonance imaging (MRI)-based) detection of significant PCa foci. The largest and most suspicious lesions detected by standardized multiparametric MRI (mpMRI) may be representative of index lesions on the final pathology and might be treated in a targeted fashion in the future. In this context, different evidence has been gathered in recent years, proposing that mpMRI and targeted biopsies be applied to men at risk of PCa even in biopsy-naïve men. In addition, MRI and clinical parameters have been integrated into various risk models, such as the most recent ERSPC risk calculator, to predict individuals’ risk of harboring a significant disease. However, whether and to what extent these improvements in diagnostics contribute to treatment or follow-up of PCa, such as in active surveillance of low-risk disease, is largely unknown and one of the key questions in current research.
This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of the science and showcase some of the latest findings in the field of personalized diagnostics and treatment in prostate cancer. Studies include those that explore the role not only of mpMRI and standard clinical parameters, but also of screening and integration of more sophisticated genomic predictors and imaging texture analysis. For follow-up of low-risk disease, the manuscripts will elucidate the role of sophisticated imaging and genomics. Lastly, for advanced and metastatic disease, the role of state-of-the-art prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging will be investigated.
Scientific advances in the field of PCa diagnostics will continue to pave the path towards personalized diagnosis and treatment.
Assoc. Prof. Dr. Jan Philipp Radtke
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Prostate cancer
- Radiomics
- MR imaging
- Radiogenomics
- Prostate cancer screening
- Prostate specific membrane antigen
- Imaging of prostate cancer at Active surveillance
- Targeted biopsy of prostate cancer
